

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10554984/publications.pdf>

Version: 2024-02-01

355
papers

36,866
citations

5876

81
h-index

3312

184
g-index

360
all docs

360
docs citations

360
times ranked

27019
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
2	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
3	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
4	Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1556.	3.8	1,759
5	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
6	Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1180.	3.8	1,143
7	Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2007, 356, 1304-1316.	13.9	921
8	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2373.	3.8	813
9	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. <i>Lancet</i> , The, 2010, 375, 1875-1884.	6.3	788
10	Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1561.	3.8	782
11	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776
12	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2078-2087.	13.9	731
13	Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 499.	3.8	654
14	Myeloperoxidase and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1102-1111.	1.1	653
15	Protein carbamylation links inflammation, smoking, uremia and atherogenesis. <i>Nature Medicine</i> , 2007, 13, 1176-1184.	15.2	601
16	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	13.9	593
17	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2268.	3.8	540
18	Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1273-1282.	1.2	467

#	ARTICLE	IF	CITATIONS
19	Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1265.	3.8	463
20	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-Câ€“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	3.8	460
21	Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical Outcome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2399-2407.	1.2	405
22	Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2099-109.	3.8	374
23	Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2006, 354, 1253-1263.	13.9	368
24	Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1547.	3.8	367
25	Position paper Statin intolerance â€“ an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
26	Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling. <i>Journal of the American College of Cardiology</i> , 2008, 52, 255-262.	1.2	296
27	Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits. <i>Circulation</i> , 2005, 111, 1543-1550.	1.6	275
28	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	3.8	270
29	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	1.0	270
30	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	3.8	247
31	Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1033-1042.	13.9	216
32	Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). <i>American Journal of Cardiology</i> , 2010, 105, 69-76.	0.7	206
33	Effect of Alogliptazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	3.8	206
34	Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis. <i>Circulation</i> , 2008, 118, 2506-2514.	1.6	200
35	Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. <i>Journal of Lipid Research</i> , 2010, 51, 1546-1553.	2.0	198
36	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012, 51, 314-324.	5.3	187

#	ARTICLE	IF	CITATIONS
37	Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography. <i>Circulation</i> , 2008, 117, 2458-2466.	1.6	186
38	Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function. <i>Journal of the American College of Cardiology</i> , 2006, 48, 715-720.	1.2	180
39	Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 838-846.	1.1	169
40	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	3.0	169
41	Effects of Normal, Pre-Hypertensive, and Hypertensive Blood Pressure Levels on Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2006, 48, 833-838.	1.2	168
42	Myeloperoxidase, modified lipoproteins, and atherogenesis. <i>Journal of Lipid Research</i> , 2009, 50, S346-S351.	2.0	168
43	Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1592-1597.	1.2	164
44	Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1111-1119.	1.2	161
45	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	0.7	151
46	Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2416-2421.	1.1	146
47	Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy. <i>Circulation</i> , 2006, 113, 2826-2834.	1.6	145
48	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	3.8	144
49	Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2736-2742.	1.2	143
50	Relationship Between Cardiovascular Risk Factors and Atherosclerotic Disease Burden Measured by Intravascular Ultrasound. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1967-1975.	1.2	142
51	Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano. <i>Journal of the American College of Cardiology</i> , 2006, 47, 992-997.	1.2	141
52	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 380-388.	0.5	139
53	Formation of Dysfunctional High-Density Lipoprotein by Myeloperoxidase. <i>Trends in Cardiovascular Medicine</i> , 2005, 15, 212-219.	2.3	138
54	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	2.3	137

#	ARTICLE	IF	CITATIONS
55	Effect of Serial Infusions of CER-001, a Pre- β^2 High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. <i>JAMA Cardiology</i> , 2018, 3, 815.	3.0	135
56	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	13.5	131
57	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. <i>JAMA Cardiology</i> , 2018, 3, 806.	3.0	129
58	Coronary Artery Calcification and Changes in Atheroma Burden in Response to Established Medical Therapies. <i>Journal of the American College of Cardiology</i> , 2007, 49, 263-270.	1.2	125
59	Effects of a Potent and Selective PPAR- α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1362.	3.8	121
60	Non-HDL Cholesterol and Triglycerides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2220-2228.	1.1	119
61	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
62	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
63	The Metabolic Syndrome, Its Component Risk Factors, and Progression of Coronary Atherosclerosis. <i>Archives of Internal Medicine</i> , 2010, 170, 478.	4.3	114
64	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. <i>Circulation</i> , 2013, 128, 2395-2403.	1.6	109
65	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 153-159.	1.2	106
66	Optical coherence tomography in coronary atherosclerosis assessment and intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 684-703.	6.1	106
67	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2201-2210.	1.2	105
68	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	3.8	103
69	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	6.1	101
70	Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 212-217.	1.4	99
71	Effect of Evolocumab on Coronary Plaque Composition. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2012-2021.	1.2	95
72	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). <i>Clinical Therapeutics</i> , 2013, 35, 1400-1411.e3.	1.1	94

#	ARTICLE	IF	CITATIONS
73	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	2.9	93
74	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 109-115.	1.0	92
75	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
76	Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. <i>Clinical Chemistry</i> , 2011, 57, 33-39.	1.5	86
77	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. <i>European Heart Journal</i> , 2013, 34, 3182-3190.	1.0	86
78	Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2315-2324.	1.6	85
79	Peripheral Arterial Disease and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1220-1225.	1.2	84
80	Intravascular imaging of vulnerable coronary plaque: current and future concepts. <i>Nature Reviews Cardiology</i> , 2011, 8, 131-139.	6.1	84
81	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 455-463.	5.5	84
82	β-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. <i>Annals of Internal Medicine</i> , 2007, 147, 10.	2.0	83
83	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 55-65.	1.0	82
84	Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. <i>Atherosclerosis</i> , 2009, 204, 424-428.	0.4	81
85	ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 181-187.	1.3	80
86	Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. <i>Atherosclerosis</i> , 2008, 196, 240-247.	0.4	79
87	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2019, 4, 314.	3.0	79
88	A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2016, 117, 1444-1448.	0.7	78
89	Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. <i>Journal of Lipid Research</i> , 2010, 51, 3055-3061.	2.0	76
90	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. <i>American Heart Journal</i> , 2015, 170, 1061-1069.	1.2	74

#	ARTICLE	IF	CITATIONS
91	Optimizing Outcomes During Left Main Percutaneous Coronary Intervention With Intravascular Ultrasound and Fractional Flow Reserve. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 697-707.	1.1	72
92	Rate of Progression of Coronary Atherosclerotic Plaque in Women. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1546-1551.	1.2	71
93	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	3.0	68
94	Coronary arterial calcification: A review of mechanisms, promoters and imaging. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 491-501.	2.3	68
95	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1135.	3.8	67
96	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , 2018, 7, e009778.	1.6	67
97	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
98	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	3.0	65
99	Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study). <i>American Journal of Cardiology</i> , 2006, 97, 1553-1557.	0.7	64
100	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	1.2	64
101	Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1110-1115.	1.2	63
102	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 460-9.	0.7	63
103	A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart Transplantation. <i>Circulation: Heart Failure</i> , 2011, 4, 129-137.	1.6	62
104	Factors underlying regression of coronary atheroma with potent statin therapy. <i>European Heart Journal</i> , 2013, 34, 1818-1825.	1.0	61
105	Redox biomarkers in cardiovascular medicine. <i>European Heart Journal</i> , 2015, 36, 1576-1582.	1.0	61
106	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. <i>European Heart Journal</i> , 2018, 39, 2551-2558.	1.0	61
107	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1091-1100.	0.8	61
108	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60

#	ARTICLE	IF	CITATIONS
109	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.	1.1	59
110	Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. <i>JAMA Cardiology</i> , 2019, 4, 437.	3.0	59
111	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1136.	3.0	59
112	Atheroma Progression in Hyporesponders to Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 990-995.	1.1	58
113	HDL and cardiovascular disease. <i>Pathology</i> , 2019, 51, 142-147.	0.3	56
114	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1013-1022.	2.3	54
115	Association Between Achieved ω -3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2021, 6, 910.	3.0	52
116	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. <i>Heart Lung and Circulation</i> , 2021, 30, 324-349.	0.2	51
117	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> , 2014, 37, 3114-3120.	4.3	50
118	Intravascular Ultrasound in Cardiovascular Medicine. <i>Circulation</i> , 2006, 114, e55-9.	1.6	49
119	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	49
120	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 45-51.	0.7	49
121	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2423-2431.	1.1	48
122	Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 744-747.	0.8	47
123	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
124	Confirmation of the Intracoronary Near-Infrared Spectroscopy Threshold of Lipid-Rich Plaques That Underlie ST-Segmentâ€Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1010-1015.	1.1	45
125	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	1.2	45
126	Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. <i>Atherosclerosis</i> , 2021, 320, 122-128.	0.4	45

#	ARTICLE	IF	CITATIONS
127	Exploring coronary atherosclerosis with intravascular imaging. <i>International Journal of Cardiology</i> , 2013, 168, 670-679.	0.8	44
128	Warfarin Use Is Associated With Progressive Coronary Arterial Calcification. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1315-1323.	2.3	44
129	Coronary Atherosclerotic Plaque Regression. <i>Journal of the American College of Cardiology</i> , 2022, 79, 66-82.	1.2	44
130	Application of intravascular ultrasound in anti-atherosclerotic drug development. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 485-492.	21.5	43
131	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Tj ETQq1 1 0.784314 rgBT /Overlock 10 Current Medical Research and Opinion, 2011, 27, 1119-1129.	0.9	43
132	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 2015, 242, 490-495.	0.4	43
133	Plaque Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1902-1910.	1.1	43
134	Paradoxical increase in lumen size during progression of coronary atherosclerosis: Observations from the REVERSAL trial. <i>Atherosclerosis</i> , 2006, 189, 229-235.	0.4	42
135	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 1465-1472.	0.7	42
136	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. <i>Journal of Clinical Lipidology</i> , 2016, 10, 519-527.e4.	0.6	42
137	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 252-263.	0.7	42
138	<i>ADCY9</i> Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2018, 3, 401.	3.0	42
139	Risk Prediction with Serial Myeloperoxidase Monitoring in Patients with Acute Chest Pain. <i>Clinical Chemistry</i> , 2011, 57, 1762-1770.	1.5	41
140	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2465-2472.	1.1	41
141	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1680.	1.8	41
142	Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 120-129.	0.7	41
143	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. <i>Atherosclerosis</i> , 2014, 232, 377-383.	0.4	40
144	Coronary atherosclerosis can regress with very intensive statin therapy.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 937-944.	0.6	40

#	ARTICLE	IF	CITATIONS
145	Evaluation of the dual peroxisome proliferator-activated receptor α/β agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. <i>American Heart Journal</i> , 2013, 166, 429-434.e1.	1.2	39
146	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. <i>Korean Circulation Journal</i> , 2016, 46, 135.	0.7	39
147	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 549-554.	0.7	37
148	Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. <i>Atherosclerosis</i> , 2019, 284, 24-30.	0.4	37
149	High-density lipoproteins as therapeutic targets. <i>Current Opinion in Lipidology</i> , 2005, 16, 345-349.	1.2	36
150	Coronary β -adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. <i>European Heart Journal</i> , 2012, 33, 495-504.	1.0	36
151	Left Main Coronary Atherosclerosis Progression, Constrictive Remodeling, and Clinical Events. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 29-35.	1.1	36
152	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
153	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	0.8	36
154	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017, 263, 137-144.	0.4	35
155	Attenuated Plaque at Nonculprit Lesions in Patients Enrolled in Intravascular Ultrasound Atherosclerosis Progression Trials. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 672-678.	1.1	33
156	Comparison of Rates of Progression of Coronary Atherosclerosis in Patients With Diabetes Mellitus Versus Those With the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2010, 105, 1735-1739.	0.7	32
157	High-Risk Coronary Atheroma. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1134-1140.	1.2	32
158	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
159	The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 49-57.	1.0	31
160	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , 2019, 290, 59-65.	0.4	30
161	Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. <i>Atherosclerosis</i> , 2017, 265, 54-59.	0.4	29
162	Comparison of Coronary Atherosclerotic Volume in Patients With Glomerular Filtration Rates ≤ 60 Versus >60 ml/min/1.73 m ² : A Meta-Analysis of Intravascular Ultrasound Studies. <i>American Journal of Cardiology</i> , 2007, 99, 813-816.	0.7	28

#	ARTICLE	IF	CITATIONS
163	Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. <i>American Heart Journal</i> , 2006, 152, 67-74.	1.2	27
164	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 209-217.	0.8	26
165	ETC-216 for coronary artery disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 387-394.	1.4	25
166	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1035-1041.	0.5	25
167	Translating Evidence of HDL and Plaque Regression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1961-1968.	1.1	25
168	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , 2018, 41, 1792-1800.	4.3	25
169	Subclinical Myocardial Necrosis and Cardiovascular Risk in Stable Patients Undergoing Elective Cardiac Evaluation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 634-640.	1.1	24
170	The Distinctive Nature of Atherosclerotic Vascular Disease in Diabetes: Pathophysiological and Morphological Insights. <i>Current Diabetes Reports</i> , 2012, 12, 280-285.	1.7	24
171	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. <i>Circulation</i> , 2015, 132, 423-432.	1.6	24
172	Managing Dyslipidemia in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 153-173.	1.2	24
173	Quantification of Nitrotyrosine Levels Using a Benchtop Ion Trap Mass Spectrometry Method. <i>Methods in Enzymology</i> , 2005, 396, 245-266.	0.4	23
174	Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 373-381.	0.8	23
175	Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1080-1087.	0.8	22
176	CETP Inhibition and HDL Cholesterol: A Story of CV Risk or CV Benefit, or Both. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 297-300.	2.3	22
177	The ASTEROID trial: coronary plaque regression with high-dose statin therapy. <i>Future Cardiology</i> , 2006, 2, 651-654.	0.5	21
178	New targets of high-density lipoprotein therapy. <i>Current Opinion in Lipidology</i> , 2007, 18, 421-426.	1.2	21
179	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
180	Cardiovascular bioimaging of nitric oxide: Achievements, challenges, and the future. <i>Medicinal Research Reviews</i> , 2021, 41, 435-463.	5.0	21

#	ARTICLE	IF	CITATIONS
181	The emerging role of plasma lipidomics in cardiovascular drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 63-72.	2.5	20
182	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <math><70\text{mg/dl}</math> or $\geq 50\%$ reduction in high-risk patients: Results from VOYAGER. <i>Atherosclerosis</i> , 2013, 228, 265-269.	0.4	20
183	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. <i>Cell Research</i> , 2006, 16, 799-808.	5.7	19
184	Peroxisome proliferator-activated receptor (PPAR α/β) agonists as a potential target to reduce cardiovascular risk in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 89-94.	0.9	19
185	Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. <i>European Heart Journal</i> , 2020, 41, 2965-2973.	1.0	19
186	Relation of High-Density Lipoprotein Cholesterol:Apolipoprotein A-I Ratio to Progression of Coronary Atherosclerosis in Statin-Treated Patients. <i>American Journal of Cardiology</i> , 2014, 114, 681-685.	0.7	18
187	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. <i>Atherosclerosis</i> , 2016, 254, 78-84.	0.4	18
188	Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. <i>Internal Medicine Journal</i> , 2017, 47, 856-865.	0.5	18
189	To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. <i>Atherosclerosis</i> , 2015, 241, 450-454.	0.4	17
190	The relationship between segmental wall shear stress and lipid core plaque derived from near-infrared spectroscopy. <i>Atherosclerosis</i> , 2018, 275, 68-73.	0.4	17
191	Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. <i>Current Opinion in Lipidology</i> , 2009, 20, 491-496.	1.2	16
192	High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1691-1701.	1.1	16
193	Exploring the Roles of CREBRF and TRIM2 in the Regulation of Angiogenesis by High-Density Lipoproteins. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1903.	1.8	16
194	Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 280-9.	0.7	16
195	Clinical trials with cholesteryl ester transfer protein inhibitors. <i>Current Opinion in Lipidology</i> , 2016, 27, 545-549.	1.2	15
196	High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. <i>Atherosclerosis</i> , 2017, 265, 110-116.	0.4	15
197	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000943.	1.2	15
198	Oral Calcium Supplements Associate With Serial Coronary Calcification. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 259-268.	2.3	15

#	ARTICLE	IF	CITATIONS
199	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.	1.3	14
200	Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. <i>Archives of Medical Science</i> , 2016, 6, 1302-1307.	0.4	14
201	CETP Inhibition in CVD Prevention: an Actual Appraisal. <i>Current Cardiology Reports</i> , 2016, 18, 43.	1.3	14
202	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. <i>BioDrugs</i> , 2017, 31, 167-174.	2.2	14
203	Rationale and design of a trial to personalize risk assessment in familial coronary artery disease. <i>American Heart Journal</i> , 2018, 199, 22-30.	1.2	14
204	Plaque Progression in Coronary Arteries With Minimal Luminal Obstruction in Intravascular Ultrasound Atherosclerosis Trials. <i>American Journal of Cardiology</i> , 2010, 105, 1679-1683.	0.7	13
205	Evacetrapib. <i>Current Cardiology Reports</i> , 2012, 14, 245-250.	1.3	13
206	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	0.9	13
207	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 282-303.	0.7	13
208	Intravascular Ultrasound and Near-Infrared Spectroscopic Characterization of Thin-Cap Fibroatheroma. <i>American Journal of Cardiology</i> , 2017, 119, 372-378.	0.7	13
209	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	1.2	13
210	HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 34-43.	0.7	13
211	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. <i>Journal of the American Heart Association</i> , 2022, 11, e024754.	1.6	13
212	Epanova [®] and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. <i>Future Cardiology</i> , 2013, 9, 177-186.	0.5	12
213	Statin-induced coronary artery disease regression rates differ in men and women. <i>Current Opinion in Lipidology</i> , 2015, 26, 276-281.	1.2	12
214	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 474-485.	0.8	12
215	Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound. <i>Journal of the American Heart Association</i> , 2020, 9, e018023.	1.6	12
216	Progression of coronary atherosclerosis in patients without standard modifiable risk factors. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100116.	1.3	12

#	ARTICLE	IF	CITATIONS
217	The mystery of evacetrapib - why are CETP inhibitors failing?. Expert Review of Cardiovascular Therapy, 2020, 18, 127-130.	0.6	12
218	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. American Journal of Preventive Cardiology, 2022, 11, 100366.	1.3	12
219	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. Current Atherosclerosis Reports, 2007, 9, 266-273.	2.0	11
220	Diabetic dyslipidemia: extending the target beyond LDL cholesterol. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, s20-s24.	3.1	11
221	Evolving targets for lipid-modifying therapy. EMBO Molecular Medicine, 2014, 6, 1215-1230.	3.3	11
222	In vivo visualization of lipid coronary atheroma with intravascular near-infrared spectroscopy. Expert Review of Cardiovascular Therapy, 2017, 15, 775-785.	0.6	11
223	Treating Dyslipidemia in Type 2 Diabetes. Cardiology Clinics, 2018, 36, 233-239.	0.9	11
224	Serial Coronary Plaque Assessment Using Computed Tomography Coronary Angiography. Circulation: Cardiovascular Imaging, 2019, 12, e008404.	1.3	11
225	Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy. Journal of the American Heart Association, 2020, 9, e014328.	1.6	11
226	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology, 2021, 20, 125.	2.7	11
227	Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. American Heart Journal, 2012, 163, 735-740.	1.2	10
228	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
229	Imaging Progression of Coronary Atherosclerosis. Circulation Journal, 2013, 77, 3-10.	0.7	9
230	CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome. British Journal of Clinical Pharmacology, 2015, 80, 1388-1398.	1.1	9
231	Anacetrapib as a potential cardioprotective strategy. Drug Design, Development and Therapy, 2017, Volume 11, 3497-3502.	2.0	9
232	Myeloperoxidase modification of high-density lipoprotein suppresses human endothelial cell proliferation and migration via inhibition of ERK1/2 and Akt activation. Atherosclerosis, 2018, 273, 75-83.	0.4	9
233	Associations of ABCG1-mediated cholesterol efflux capacity with coronary artery lipid content assessed by near-infrared spectroscopy. Cardiovascular Diagnosis and Therapy, 2019, 9, 310-318.	0.7	9
234	Status of PCSK9 Monoclonal Antibodies in Australia. Heart Lung and Circulation, 2019, 28, 1571-1579.	0.2	9

#	ARTICLE	IF	CITATIONS
235	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 171-177.	0.9	9
236	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. <i>Diabetes Care</i> , 2020, 43, e22-e24.	4.3	9
237	Rosuvastatin and progression of atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 925-933.	0.6	8
238	Lessons from Coronary Intravascular Ultrasound on the Importance of Raising High-Density Lipoprotein Cholesterol. <i>Current Atherosclerosis Reports</i> , 2010, 12, 301-307.	2.0	8
239	Coronary Endothelium-Dependent Vasoreactivity and Atheroma Volume in Subjects With Stable, Minimal Angiographic Disease Versus Non-“ST-Segment” Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 674-682.	1.3	8
240	Exploring the natural history of atherosclerosis with intravascular ultrasound. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 295-306.	0.6	7
241	High-Density Lipoprotein and Progression Rate of Atherosclerosis in Intravascular Ultrasound Trials. <i>American Journal of Cardiology</i> , 2009, 104, 16E-21E.	0.7	7
242	Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1383-1390.	0.6	7
243	Current imaging modalities for atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 457-471.	0.6	7
244	Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 328-329.	1.2	7
245	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1331-1339.	0.8	7
246	Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review. <i>Current Medical Research and Opinion</i> , 2016, 32, 1143-1150.	0.9	7
247	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 122-132.	1.2	7
248	Lipid Lowering Therapy to Modify Plaque Microstructures. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
249	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 435-443.	0.7	7
250	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2522-2533.	1.8	7
251	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 343-348.	1.0	7
252	Progression of coronary atherosclerosis in African-American patients. <i>Cardiovascular Diagnosis and Therapy</i> , 2013, 3, 161-9.	0.7	7

#	ARTICLE	IF	CITATIONS
253	HDL: still a target for new therapies?. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 950-6.	2.3	7
254	Recent trends in coronary intravascular ultrasound: Tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 91-96.	1.4	6
255	Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1471-1489.	0.6	6
256	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. <i>Vascular Health and Risk Management</i> , 2015, 11, 203.	1.0	6
257	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	0.9	6
258	Implications of GLAGOV study. <i>Current Opinion in Lipidology</i> , 2017, 28, 465-469.	1.2	6
259	The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. <i>Current Cardiology Reports</i> , 2019, 21, 18.	1.3	6
260	Quantitative and Qualitative Coronary Plaque Assessment Using Computed Tomography Coronary Angiography: A Comparison With Intravascular Ultrasound. <i>Heart Lung and Circulation</i> , 2020, 29, 883-893.	0.2	6
261	Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 1297-1312.	0.4	6
262	Apo A-I Modulating Therapies. <i>Current Cardiology Reports</i> , 2011, 13, 537-543.	1.3	5
263	â€œFramingâ€the Vessel. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1038-1039.	1.2	5
264	Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 247-257.	0.7	5
265	Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1721-1723.	2.3	5
266	Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. <i>Cardiology</i> , 2018, 140, 30-34.	0.6	5
267	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020, 221, 60-66.	1.2	5
268	Tackling cardiometabolic risk in the Asia Pacific region. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100096.	1.3	5
269	The fish-oil paradox. <i>Current Opinion in Lipidology</i> , 2020, 31, 356-361.	1.2	5
270	Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 12, 0-0.	0.7	5

#	ARTICLE	IF	CITATIONS
271	New Cardiovascular Risk Assessment Techniques for Primary Prevention. <i>Journal of the American College of Cardiology</i> , 2022, 80, 373-387.	1.2	5
272	Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. <i>Current Atherosclerosis Reports</i> , 2010, 12, 14-19.	2.0	4
273	Strategies for the development of new PPAR agonists in diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s32-s37.	3.1	4
274	Is It Time for HDL to Change Its Tune?. <i>Circulation</i> , 2013, 128, 1175-1176.	1.6	4
275	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	2.0	4
276	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. <i>American Journal of Cardiology</i> , 2016, 118, 1616-1623.	0.7	4
277	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.	1.2	4
278	Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis. <i>Archives of Medical Science</i> , 2017, 1, 210-214.	0.4	4
279	Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 405-413.	0.7	4
280	Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 707-716.	0.6	4
281	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 113-131.	1.0	4
282	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 30-38.	2.2	4
283	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. <i>Internal Medicine Journal</i> , 2021, 51, 769-779.	0.5	4
284	An update on emerging drugs for the treatment of hypercholesterolemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 363-369.	1.0	4
285	HbA1c, Coronary atheroma progression and cardiovascular outcomes. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100317.	1.3	4
286	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	1.2	4
287	Emerging Role of Intravascular Ultrasound in the Assessment of Experimental Anti-Atherosclerotic Therapies. <i>Current Medicinal Chemistry</i> , 2006, 13, 1727-1734.	1.2	3
288	Predicting the Future. <i>Circulation</i> , 2012, 126, 161-162.	1.6	3

#	ARTICLE	IF	CITATIONS
289	Acute high-density lipoprotein therapies. <i>Current Opinion in Lipidology</i> , 2015, 26, 521-525.	1.2	3
290	Lipid Biomarkers and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1296-1297.	1.2	3
291	Men and women “ similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration. <i>Future Cardiology</i> , 2015, 11, 511-515.	0.5	3
292	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. <i>Atherosclerosis</i> , 2015, 243, 553-559.	0.4	3
293	Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 121-129.	0.7	3
294	What role for lipoprotein(a) in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 487-489.	5.5	3
295	High-Density Lipoprotein Infusions. <i>Cardiology Clinics</i> , 2018, 36, 311-315.	0.9	3
296	The time for lipoprotein(a) based intervention has arrived: where will the light shine?. <i>Journal of Thoracic Disease</i> , 2019, 11, S433-S436.	0.6	3
297	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e013790.	1.6	3
298	The role of intracoronary imaging in translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1480-1507.	0.7	3
299	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100151.	1.3	3
300	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 85-93.	0.6	2
301	Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 753-761.	2.5	2
302	High-Density Lipoprotein: Is the Good Cholesterol Turning Bad?. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 18-28.	0.8	2
303	Is Lp(a) Ready for Prime Time?—. <i>Journal of the American College of Cardiology</i> , 2014, 64, 861-862.	1.2	2
304	Response to Comment on Stegman et al. High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> 2014;37:3114-3120. <i>Diabetes Care</i> , 2015, 38, e28-e29.	4.3	2
305	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
306	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 447-452.	1.0	2

#	ARTICLE	IF	CITATIONS
307	Monitoring the Response to Statin Therapy. JACC: Cardiovascular Imaging, 2018, 11, 1485-1486.	2.3	2
308	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. American Journal of Preventive Cardiology, 2020, 3, 100091.	1.3	2
309	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk Reply. JAMA - Journal of the American Medical Association, 2021, 325, 1334.	3.8	2
310	Targeting triglycerides to lower residual cardiovascular risk. Expert Review of Cardiovascular Therapy, 2022, , 1-7.	0.6	2
311	Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. JACC: Cardiovascular Imaging, 2022, 15, 709-711.	2.3	2
312	Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol $\leq 55\text{ mg/dL}$. JACC: Cardiovascular Imaging, 2022, 15, 1166-1169.	2.3	2
313	Impact of statins on atherosclerotic plaque. Future Cardiology, 2007, 3, 157-164.	0.5	1
314	High-density lipoprotein and atheroma monitoring. Current Opinion in Cardiology, 2008, 23, 386-392.	0.8	1
315	Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis. Current Medical Research and Opinion, 2010, 26, 745-751.	0.9	1
316	Rationale and approach to evaluation of the impact of medical therapies on progression of atherosclerosis with arterial wall imaging. Current Medical Research and Opinion, 2010, 26, 737-744.	0.9	1
317	Imaging coronary atherosclerosis: is there space for magnetic resonance imaging?. Expert Review of Cardiovascular Therapy, 2013, 11, 383-385.	0.6	1
318	Left main coronary arterial endothelial function and heterogenous segmental epicardial vasomotor reactivity in vivo: novel insights with intravascular ultrasonography. European Heart Journal Cardiovascular Imaging, 2014, 15, 1270-1280.	0.5	1
319	Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER. IJC Metabolic & Endocrine, 2014, 5, 61-66.	0.5	1
320	Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?. , 2015, , 65-71.		1
321	Will genetic studies deliver the next generation of cardioprotective therapies?. European Journal of Preventive Cardiology, 2017, 24, 489-491.	0.8	1
322	PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. Current Cardiology Reports, 2017, 19, 66.	1.3	1
323	Evaluation of human coronary vasodilator function predicts future coronary atheroma progression. Heart, 2018, 104, 1439-1446.	1.2	1
324	High-Density Lipoprotein Targeted Therapies Not Dead Yet Reply. JAMA Cardiology, 2018, 3, 1255.	3.0	1

#	ARTICLE	IF	CITATIONS
325	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 259-266.	0.8	1
326	Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors. European Cardiology Review, 2018, 13, 9.	0.7	1
327	Combining cholesterol-lowering strategies with imaging data: a visible benefit?. European Journal of Preventive Cardiology, 2019, 26, 365-379.	0.8	1
328	Using genetics to guide treatment and drug development in cardiovascular medicine: time to reveal the proof in the pudding. Cardiovascular Research, 2020, 116, e30-e32.	1.8	1
329	Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?. JACC: Cardiovascular Imaging, 2021, 14, 1174-1176.	2.3	1
330	Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. , 2009, , 410-419.		1
331	Residual Risk and Biology of the Disease: Implications for Plaque Imaging. Contemporary Cardiology, 2014, , 1-21.	0.0	1
332	The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology, 2006, 1, 421-428.	0.5	0
333	Atherosclerosis imaging in drug development. Expert Opinion on Drug Discovery, 2007, 2, 1241-1250.	2.5	0
334	Impact Of Statin Therapy On The Artery Wall In The Low-Risk Patient: Implications From The METEOR Study. Future Lipidology, 2007, 2, 595-601.	0.5	0
335	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. Current Cardiovascular Risk Reports, 2007, 1, 290-295.	0.8	0
336	Response to Letters Regarding Article, "Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden". Circulation, 2008, 118, .	1.6	0
337	Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs. Current Cardiovascular Imaging Reports, 2010, 3, 190-196.	0.4	0
338	Will apoA-I-based therapies step up to cure coronary artery disease?. Expert Review of Cardiovascular Therapy, 2011, 9, 1367-1370.	0.6	0
339	Intracoronary IVUS for Evaluation of Atherosclerosis Progression. Current Cardiovascular Imaging Reports, 2012, 5, 239-248.	0.4	0
340	Intracoronary Optical Coherence Tomography. Journal of the American College of Cardiology, 2013, 62, 1759-1760.	1.2	0
341	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. Current Cardiovascular Risk Reports, 2013, 7, 60-65.	0.8	0
342	Examining controversies and new frontiers in lipid management. Clinical Lipidology, 2014, 9, 587-595.	0.4	0

#	ARTICLE	IF	CITATIONS
343	Intravascular Ultrasound Studies of Plaque Progression and Regression. <i>Cardiology Clinics</i> , 2018, 36, 329-334.	0.9	0
344	Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?. <i>EClinicalMedicine</i> , 2018, 4-5, 6-7.	3.2	0
345	Vascular calcification in response to pharmacological interventions. , 2019, , 181-189.		0
346	Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 229-235.	1.0	0
347	Inflammatory Markers and Novel Risk Factors. <i>Contemporary Cardiology</i> , 2019, , 87-98.	0.0	0
348	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 11-18.	1.0	0
349	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. <i>Future Cardiology</i> , 2020, 16, 343-350.	0.5	0
350	Intravascular Ultrasound. , 2009, , 83-93.		0
351	Inflammatory Markers and Novel Risk Factors. , 2011, , 107-123.		0
352	Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. <i>Journal of the Japanese Coronary Association</i> , 2014, 20, 282-294.	0.0	0
353	Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. <i>Contemporary Cardiology</i> , 2014, , 67-79.	0.0	0
354	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 217-227.	0.0	0
355	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0